Top 10 mergers and acquisitions in biopharmaceuticals worldwide in 2020

Pharma.com, January 5 (Xinhua) -- Mergers and acquisitions are an important means for large pharmaceutical companies to expand their research and development pipelines and scale up their scale, and the number and amount of major mergers and acquisitions in the world will decrease significantly in 2020 compared with 2019, with the total value of the world's top 10 mergers and acquisitions amounting to $136.7 billion, only 50% of last year's total.
addition, it is worth noting that the impact of the outbreak, Thermo Fliesel's $11.6 billion acquisition of QIAGEN failed.
table 1: Top 10 mergers and acquisitions in the global biopharmaceutical sector by 2020 Source: Firestone Creates a $39 billion acquisition of AstraZeneta Pharmaceuticals in the United States Based on publicly available information In December 2020, global pharmaceutical giant AstraZene announced that it would acquire biotech company Alequil Pharmaceuticals of the United States for $39 billion to strengthen its position in the field of immunology and rare diseases.
Alepi Pharmaceuticals is committed to researching innovative rare disease products, the core product is the treatment of atypical hemolytic uremic syndrome and aphpathic nocturnal hemohemophilia drug Soliris, the drug in 2019 sales of $3,946 million, is one of the world's best-selling TOP20 drugs.
's $21 billion acquisition of Immunomedics in September 2020, global pharmaceutical giant Gilead announced that it would buy biotech company Immunomedics for $21 billion, a move that will accelerate Gilead's foray into cancer.
Immunomedics is a pioneer in next-generation antibody drug concedes (ADCs).
In April, the company's first commercial ADC product, Trodelvy, received accelerated FDA approval to treat adult patients with metastasis triple-negative breast cancer (mTNBC), which has been treated with at least two therapies for metastasis, and was the first FDA-approved specialized treatment for relapse or refractive mTNBC and the first targeted Trap-2 ADC drug.
's $18.5 billion acquisition of Livongo in August 2020, Teladoc Health, a U.S. telemedican services company, announced that it would buy Livongo, a slow-motion digital management company, for $18.5 billion, with the combined company valued at about $38 billion.
Livongo was founded in 2014 to help people with chronic diabetes manage their blood sugar information through technical tools, and its diabetes management approach, Livongo for Diabetes, consists of a team of connected devices InTouch®, Smart Cloud and Virtual Care.
Among them, InTouch® device can achieve cellular network connectivity, equipped with a color touch screen, is both a blood glucose monitor, but also a spectrometer, can read the user's glycemic index, send information to the monitoring service center, the user will receive the company's recommendation after the blood sugar reading beyond the normal range, if the blood sugar reading is seriously outside the normal range, the user will immediately receive an expert call.
Siemens Medical's $16.4 billion acquisition of Valian in August 2020, Siemens Medical, a Leading German medical technology company, announced that it would acquire Valian Medical Systems, a U.S. cancer medical technology manufacturer, for $16.4 billion.
's combined company will focus on developing a fully integrated platform covering end-to-end cancer solutions to ensure continuity in cancer care: from screening and diagnosis, treatment care, to post-treatment survival processes.
By combining the highly complementary diagnostic tools, imaging, radiotherapy and artificial intelligence capabilities of the two companies, Valian and Siemens Medical will lead the digital transformation of cancer therapy to enable more efficient diagnosis, higher quality treatment, and a wider range of access and more personalized precision cancer treatments to improve the effectiveness of treatment for millions of patients worldwide.
$13.1 billion cash acquisition of MyoKardia in October 2020, Shishi Shishi said it would buy MyoKardia, a heart drug company, for $13.1 billion.
MyoKardia is a clinical biopharmaceutical company dedicated to the discovery and development of targeted therapies for severe cardiovascular disease, the main drug mavacamten, a potential "first-in-class" cardiovascular drug for the treatment of hypertrophy cardiomyopathy (HCM).
between 160,000 and 200,000 people in the United States and the European Union have been diagnosed with obstructive HCM.
hundred-time Meishi Shiguibo has high hopes for mavacamten, calling it a "first-class cardiovascular drug" for the treatment of HCM.
$ 8 billion acquisition of Grail in September 2020, the global gene sequencing giant Willumina will buy blood testing company Grail for $8 billion in cash and stock.
was originally founded by Illumina, but split from Illumina in 2016 with the goal of developing simple blood tests to achieve cancer screening.
Grail plans to launch a multi-cancer blood screening test called Gallei next year, relying on targeted methylation sequencing technology.
's $6.5 billion acquisition of Momenta Pharmaceuticals in August 2020, global pharmaceutical giant Johnson and Johnson announced it would buy Momenta, a U.S. drugmaker, for $6.5 billion.
Momenta is a biopharmaceutical company focused on rare immunometric diseases whose core product is the anti-FcRn monoantigen Nipocalimab, which is currently in the clinical phase III.
s $4.9 billion acquisition of Forty Seven in March 2020, Gilead Sciences announced that it would buy Forty Seven, which develops CD47 path inhibitors, for a total of $4.9 billion in cash.
acquisition, Gilead will further strengthen its research and development portfolio in the field of immuno-oncology.
Forty Seven is a company focused on clinically stage immuno-oncology with a core product of the single anti-drug magolimab for multiple cancers, which has been approved by the FDA for rapid approval and rare diseases.
Blackstone's $4.7 billion acquisition of Ancestry in August 2020, blackstone, the global private equity giant, announced it would buy Ancestry, a gene genealogy website, for $4.7 billion.
's acquisition focuses on the potential of Ancestry's genealogy tracking and personalized drug business.
, the world's largest PROVIDER of DNA services, has genetically typed 18 million people.
users can trace genealogy through DNA home testing and obtain genetic health risk reports.
currently has 3 million paying customers in about 30 countries and annual revenue of more than $1 billion.
GSK's proposed $4.6 billion acquisition of Eidos Therapeutics in November 2020, global pharmaceutical giant GlaxoSmithKline made an offer to buy Eidos Therapeutics for $4.6 billion.
, Eidos Therapeutics focuses on meeting unseatable treatment needs by discovering and developing new oral therapies for the treatment of thyroxine protein (TTR) amyloid degeneration (ATTR).
the company is developing a small molecule called acoramidis (AG10) that stabilizes the TTR by combining AG10 with the tetrogen TTR to produce strong molecular bonds.
failure: Thermo Fliesel's $11.6 billion acquisition of QIAGEN failed In March 2020, global instrumentation and diagnostic reagents giant Thermo Fliesel announced that it would buy German diagnostic company QIAGEN for about $11.6 billion.
QIAGEN is a leading provider of life sciences and molecular diagnostic solutions, with approximately 5,100 employees in 35 locations in 25 countries.
acquisition was originally scheduled to be completed by the first half of 2021, but as the new crown epidemic spread, global demand for COVID-19 diagnostic reagents and molecular testing reagents increased dramatically, resulting in a significant increase in QIAGEN's business volume and a sharp rise in its share price.
the end, QIAGEN shareholders rejected Thermo's offer, even if Thermo wanted to raise the price to $15 billion.
August 2020, Seymru announced that it was terminating its acquisition of QIAGEN and that its agreement to acquire all common shares of QIAGEN was void.
the termination of the acquisition agreement, QIAGEN will pay Thermo Fly Cash $95 million in reimbursements under the terms of the agreement.
。